Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Mastocytosis: impact of COVID-19 on clinical practice

Cem Akin • 10 Jun 2020
EHA 2020
General Myeloproliferative Neoplasms Systemic Mastocytosis

Cem Akin MD, PhD, of the University of Michigan, Ann Arbor, MI, discusses the impact of COVID-19 in mastocytosis clinical practice. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Cem Akin

1:43
ddPCR detects KIT D816V mutations with high sensitivity in systemic mastocytosis
Cem Akin • 11 Dec 2020
5:14
Avapritinib for indolent systemic mastocytosis in the PIONEER trial
Cem Akin • 11 Dec 2020
9:29
PIONEER: avapritinib in patients with indolent systemic mastocytosis
Cem Akin • 10 Jun 2020

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals